| Info Sheets |
| | | | | | | | | | | | | | | | | | | | | | | | |
| Out- side |
| | | | |
|
| | | | |
Result : Searchterm 'Relaxivity' found in 1 term [] and 50 definitions []
| previous 11 - 15 (of 51) nextResult Pages : [1] [2 3 4 5 6 7 8 9 10 11] | | | | | | |
| |
|
Drug Information and Specification
r1=25, r2=160, B0=0.47T, r1=23.3, r2=48.9, B0=0.47T
PHARMACOKINETIC
Vascular, lymph v. hepatocyte (AG-USPIO)
PREPARATION
Suspend in an isotonic glucose solution
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING
PACKAGE INSERT!
| | | | • View the NEWS results for 'Combidex®' (1).
| | | | Further Reading: | | Basics:
|
|
News & More:
| |
| |
| | | | | |
| |
|
Drug Information and Specification
T1, Predominantly positive enhancement
PHARMACOKINETIC
Intravascular, extracellular, renal excretion
DOSAGE
0.1 mmol/kg / 0.2mL/kg
PREPARATION
Finished product
INDICATION
Neuro/whole body
DEVELOPMENT STAGE
For sale
PRESENTATION
Vials of 5, 10, 15, 20mL Pre-filled syringes of 15 and 20 mL
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING
PACKAGE INSERT!
Distribution Information
TERRITORY
TRADE NAME
DEVELOPMENT STAGE
DISTRIBUTOR
France, Switzerland
Artirem®
for sale
| | | | • View the DATABASE results for 'Dotarem®' (7).
| | | | Further Reading: | Basics:
|
|
News & More:
| |
| |
| | | | | |
| |
|
Some dyamides are under preclinical development as intravascular MRI contrast agents for blood flow perfusion.
Short name: Dy-DTPA-BMA, generic name: Sprodyamide, central moiety: Dy2+, contrast effect: T2*enhanced, relaxivity: r1=3.4, r2=3.8, B0=0.47,
Short name: Dy-DTPA, central moiety: Dy2+, contrast effect: T2*enhanced,
Short name: Albumin-(Dy-DTPA)x, central moiety: Dy2+, contrast effect: T2*enhanced.
| | | | | Further Reading: | Basics:
|
|
| |
| | | | | | | | | | | | | | |
| | | |
|
| |
| Look Ups |
| |